🍪 The GLP Lounge uses cookies to improve your experience, analyze traffic, and personalize content. By continuing to use this site, you agree to our Cookie Policy.
Evidence-based GLP-1 & peptide discussion since 2023
ForumsMetabolic Health & DiabetesSURPASS-CVOT: tirzepatide cardiovascular outcomes trial design — looking for input Page 5

SURPASS-CVOT: tirzepatide cardiovascular outcomes trial design — looking for input

Admin Sat, Jul 12, 2025 at 7:09 AM 40 replies 1,896 viewsPage 5 of 8
FitDadDave
Member
534
2,678
Jul 2024
Minneapolis, MN
Aug 14, 2025 at 4:58 PM#21
TrialTracker_MD said:
One practical note: write down what you did and when, before you need it.

Genuinely useful, thank you. I had the facts and not the framework. Sending this to two other people who asked me the same thing last week.

2 0Dr.NephBHM_UK, kim_atl_prep
Reply Quote Save Share Report
KevinCompounds
VIP Member
5,432
18,234
Dec 2023
Nevada
Aug 28, 2025 at 7:54 AM#22

From the other side of the consultation, briefly. Take it one variable at a time. Almost every unanswerable question in these threads is unanswerable because three things changed in the same fortnight, and no amount of subsequent argument can untangle them after the fact.

3 1Dr.RaviCardio, jennifer_SEA, tyler_CSCS
Reply Quote Save Share Report
B12Beth
Member
289
890
Oct 2024
Maryland
Sep 10, 2025 at 10:42 PM#23
KevinCompounds said:
Almost every unanswerable question in these threads is unanswerable because three things changed in the same fortnight, and no amount of subsequent…

Same pattern here, and in the same order. Posting only so the count is not one.

4 2DanielChem_CHI, marco_milano, pam_columbus and 1 other
Reply Quote Save Share Report

Janoshik Analytical — Independent Testing

Trusted third-party HPLC & mass spectrometry analysis. Verify peptide purity with the lab the community relies on. Independent. Accurate. Transparent.

Verify Your Peptides

GL Biochem (Shanghai) Ltd. — Direct Manufacturer

Est. 1998. The synthesis house behind the vials you send for testing. ISO 9001 and cGMP certified, 1,500+ staff, batch-specific COA with every order.

Browse GL Biochem
julia.endo
Senior Member
1,890
9,012
Feb 2024
Cincinnati, OH
Sep 24, 2025 at 1:22 PM#24
KevinCompounds said:
Almost every unanswerable question in these threads is unanswerable because three things changed in the same fortnight, and no amount of subsequent…

Coming at KevinCompounds’s question from a different direction. The honest answer is that the effect is real, the magnitude is contested, and the individual variation is larger than either. Those three things can all be true at once, and most arguments here are two people holding different parts of that.

5 3jason_sac26, chris_chi24, tampaLisa73 and 2 others
Reply Quote Save Share Report
BiostatsBrad
Member
456
2,345
Jul 2024
Durham, NC
Oct 8, 2025 at 3:54 AM#25

Adding the numbers, since they settle part of this. For anyone reading later: the numbers in this thread are worth checking against a primary source before you act on them, including mine. Half the figures circulating in this community trace back to a secondary summary that dropped a qualifier.

Worth separating that from cardiovascular outcomes, which this thread keeps folding into the same question. They behave differently and the advice does not transfer.

6 4NicoleRaleigh, james_edin, FranDenver and 3 others
Reply Quote Save Share Report

Similar Threads

SUSTAIN-6 to SELECT — the cardiovascular evidence timeline14 replies
GLP-1 and insulin resistance — HOMA-IR improvement data17 replies
Metabolic syndrome reversal criteria — how GLP-1 addresses all 55 replies
A1C target achievement rates — sema vs tirz comparison8 replies
SURPASS-CVOT: tirzepatide cardiovascular outcomes trial design3 replies
ForumsNewTrendingMembersAccount

Log In

Forgot password?
No account? Register